Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Glioblastoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Sidney Kimmel Comprehensive Cancer Center.